Abstract: For the treatment of lipoproteinaemia and arteriosclerosis, the new disubstituted pyridines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heteroaryl,R.sup.2 is cycloalkyl or optionally substituted alkyl,R.sup.3 is hydrogen, cycloalkyl, or optionally substituted alkyl, aryl or heteroaryl,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,A is ##STR2## R.sup.6 is hydrogen or alkyl, and R.sup.7 is hydrogen, alkyl, aralkyl or a cation.

Abstract: Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula ##STR1## in which A, B, D and E can have varied meanings,X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, andR is ##STR2## wherein R.sup.21 --denotes hydrogen or alkyl andR.sup.22 --denotes hydrogen,denotes alkyl, aryl or aralkyl, ordenotes a cation,and their oxidation products.

Abstract: Substituted pyridyl-dihydroxy-heptenoic acid of the formula ##STR1## and its salts, if desired in an isomeric form, have a superior inhibitory action on HMG-CoA reductase and thus bring about a surprisingly good lowering of the cholesterol content in the blood.

Abstract: For the treatment of lipoproteinaemia and arteriosclerosis, the polysubstituted pridines of the formula ##STR1## in which R.sup.1 is optionally substituted furyl or thienyl,R.sup.2 is cycloalkyl or optionally substituted alkyl,R.sup.3 is hydrogen, cycloalkyl, or optionally substituted alkyl, aryl or heteroaryl,X is --CH.dbd.CH--,A is ##STR2## R.sup.6 is hydrogen or alkyl, and R.sup.7 is hydrogen, alkyl, aralkyl or a cation.

Abstract: Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula ##STR1## in which A, B, D and E can have varied meanings,X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, andR is ##STR2## wherein R.sup.21 denotes hydrogen or alkyl andR.sup.22denotes hydrogen,deontes alkyl, aryl or aralkyl, ordenotes a cation,and their oxidation products.

Abstract: For inhibiting HMG-CoA reductase and cholesterol synthesis, the novel 2-pyridones and pyrid-2-thiones of the formula ##STR1## in which A is optionally substituted aryl or heterocyclic,B is optionally substituted alkyl, cycloalkyl or aryl,D and E independently are optionally substituted aryl or heterocyclic, H, nitro, cyano, optionally substituted alkyl, alkenyl or imino, amino, alkoxy or acyl, or forms a ring with B,G is O or S,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, andR represents a group of the formula ##STR2## and salts thereof.

Abstract: Substituted pyrido(2,3-d) pyrimidines of the formula: ##STR1## useful as intermediates for the preparation of MMG-CoA reductase inhibitors.

Abstract: A deuterium lamp with a quartz glass bulb for spectral analyzers is disclosed. At least the portion of the quartz glass bulb through which the radiation produced passes is provided on its outer surface with a multiple interference filter layer; the physical layer thickness of each layer is in the range from 10 to 70 nm. The multiple layer comprises atlternating aluminum oxide and silicon dioxide, or magnesium fluoride. The interference filter layers are preferably vapor-deposited in a vacuum.

Abstract: New substituted pyrido(2,3-d)pyrimidines of the formula ##STR1## can be prepared by reduction of corresponding pyrido(2,3-d)-pyrimidines which are substituted by a ketone radical, and subsequent hydrolysis, cyclization or hydrogenation. The new compounds can be used to inhibit HMG-CoA reductase.

Abstract: For inhibiting HMG-CoA reductase and cholesterol synthesis, the novel 2-pyridones and pyrid-2-thiones of the formula ##STR1## in which A is optionally substituted aryl or heterocyclic,B is optionally substituted alkyl, cycloalkyl or aryl,D and E independently are optionally substituted aryl or heterocyclic, H, nitro, cyano, optionally substituted alkyl, alkenyl or imino, amino, alkoxy or acyl, or forms a ring with B,G is O or S,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, andR represents a group of the formula ##STR2## and salts thereof.

Abstract: Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula ##STR1## in which A, B, D and E can have varied meanings,X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--, andR is ##STR2## wherein R.sup.21 denotes hydrogen or alkyl andR.sup.22denotes hydrogen,denotes alkyl, aryl or aralkyl, ordenotes a cation,and their oxidation products.

Abstract: For inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, the novel substituted pyrroles of the formula ##STR1## in which R.sup.1 is optionally alkyl or cycloalkyl,R.sup.2 and R.sup.3 each is optionally substituted aryl or heteroaryl,R.sup.4 is H or an organic radical,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,A is ##STR2## R.sup.7 is H or alkyl, and R.sup.8 is H or an ester or cation radical.Novel intermediates therefor are also provided.

Abstract: Inhibiting HMG-CoA reductase, as in treating hyperlipopproteinaemia, lipoproteinaemia and arteriosclerosis, with the new N-substituted N-amino-pyrroles of the formula ##STR1## in which R.sup.1 is an organic radical,R.sup.2 is an aryl or heteroaryl radical,R.sup.3 is a hydrogen or an organic radical,R.sup.4 and R.sup.5 each independently is hydrogen or an organic radical or, together, they complete a heterocylic ring,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,A is ##STR2## R.sup.10 is hydrogen or alkyl, and R.sup.11 is hydrogen, an organic radical or a cation.

Abstract: HMG-CoA reductase-inhibiting compounds of the formula ##STR1## in which R.sup.1 is an optionally substituted alkyl as cycloalkyl radical,R.sup.2 is an optionally substituted aryl or heteroaryl radical,R.sup.3 is hydrogen or an organic radical,B is O or S,X is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--,A is ##STR2## R.sup.6 is hydrogen or alkyl, and R.sup.7 is hydrogen, alkyl, aralkyl, aryl or a cation.

Abstract: For inhibiting 3-hydroxy-3-methylglutaryl coenzyme A and cholesterol biosynthesis, the novel disubstituted pyrroles of the formula ##STR1## in which R.sup.1 is aryl or heteroaryl,R.sup.2 is cycloalkyl or optionally substituted alkyl,R.sup.3 is hydrogen or cycloalkyl, or optionally substituted alkyl, aryl or heteroaryl,X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,A is ##STR2## R.sup.6 is hydrogen or alkyl, and R.sup.7 is hydrogen, a cation or alkyl, aryl or aralkyl.

Abstract: To protect the quartz of a quartz glass bulb (2) from attack by alkaline earth oxides emitted from electrodes (6) of the lamp, and prevent deterioration of the quartz in use of the lamp with respect to transmission of ultraviolet (UV) radiation, particularly in the short wave length range of 200 nm to 250 nm, boron silicate glass or glass-like aluminum oxide, or a mixture of boron silicate glass and glass-like aluminum oxide is interposed between the quartz bulb (2) and the electrodes. Boron oxide can be applied to the interior of the quartz bulb, and fired thereon to form, for example, a boron silicate glass layer (4) or diffuse into the quartz glass to form a diffusion layer (4') by suitable selection of firing temperatures. Alternatively, an aperture support element (35, 45) can retain a disk of boron silicate glass or glass-like aluminum oxide positioned between the electrodes and the quartz glass bulb.

Abstract: A composition effective for treating circulation disorders comprises a mixture of ##STR1## wherein the variables can have varied meetings. I are inotropic and II are vasodilating but, whereas the ingredients in the combination would be expected to be antagonistic, they are reinforcing.

Abstract: Circulatory system-active novel dihydropyrimidines of the formula ##STR1## in which R.sup.1 and R.sup.6 are diverse organic radicals, and pharmacologically acceptable addition salts thereof.

Abstract: 5-Aryl-1,4-dihydropyridines of the formula ##STR1## in which Rrepresents cycloalkyl,heteroaryl oraryl which is optionally substituted by at least one substituent independently selected from the group consisting of halogen, nitro, hydroxyl, amino, carboxyl, alkoxycarbonyl, cyano, acyl, acyloxy, acylthio, by alkyl, alkyloxy, alkylthio or alkylsulphonyl, each of which is optionally substituted by one or more halogens, by aryl which is optionally substituted by alkyl, alkoxy, halogen or nitro, or optionally by the group --Z--CH.sub.2 --R.sup.4,whereZ represents oxygen or sulphur, andR.sup.4represents cycloalkyl,heteroaryl oraryl which is optionally substituted by halogen, cyano, nitro, hydroxyl, carboxyl, alkoxycarbonyl or by alkyl or alkoxy, each of which is optionally substituted by one or more halogens,R.sup.1 and R.sup.2are identical or different andrepresent straight-chain or branched alkyl which is optionally substituted by aryl, carboxyl, alkoxycarbonyl or by hydroxyl,R.sup.

Abstract: Novel circulation active dihydropyridines of the formula ##STR1## in which X is CO, SO.sub.2 or CONH,R.sup.4 is H, OH, alkyl, halogen, acyloxy, alkoxyalkoxy, aralkyloxy, or together with R.sup.5 forms a heterocyclic ring, andthe other radicals are conventional in the dihydropyridine art,and pharmaceutically acceptable salts thereof.